[go: up one dir, main page]

AP2986A - Modulators of pharmacokinetic properties of therapeutics - Google Patents

Modulators of pharmacokinetic properties of therapeutics

Info

Publication number
AP2986A
AP2986A AP2009004964A AP2009004964A AP2986A AP 2986 A AP2986 A AP 2986A AP 2009004964 A AP2009004964 A AP 2009004964A AP 2009004964 A AP2009004964 A AP 2009004964A AP 2986 A AP2986 A AP 2986A
Authority
AP
ARIPO
Prior art keywords
therapeutics
modulators
pharmacokinetic properties
pharmacokinetic
properties
Prior art date
Application number
AP2009004964A
Other languages
English (en)
Other versions
AP2009004964A0 (en
Inventor
Manoj C Desai
Allen Y Hong
Hon C Hui
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39522375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2986(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2009004964A0 publication Critical patent/AP2009004964A0/xx
Application granted granted Critical
Publication of AP2986A publication Critical patent/AP2986A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2009004964A 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics AP2986A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90322807P 2007-02-23 2007-02-23
US95871607P 2007-07-06 2007-07-06
PCT/US2008/054788 WO2008103949A1 (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics

Publications (2)

Publication Number Publication Date
AP2009004964A0 AP2009004964A0 (en) 2009-10-31
AP2986A true AP2986A (en) 2014-09-30

Family

ID=39522375

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2013007042A AP3915A (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics
AP2009004964A AP2986A (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AP2013007042A AP3915A (en) 2007-02-23 2008-02-22 Modulators of pharmacokinetic properties of therapeutics

Country Status (31)

Country Link
US (7) US8148374B2 (xx)
EP (5) EP3689353A1 (xx)
JP (9) JP4881446B2 (xx)
KR (2) KR101664154B1 (xx)
CN (2) CN103435570B (xx)
AP (2) AP3915A (xx)
AR (1) AR065439A1 (xx)
AU (1) AU2008218186C1 (xx)
BR (1) BRPI0807581A2 (xx)
CA (1) CA2678907C (xx)
CY (9) CY1118292T1 (xx)
DK (2) DK2487166T3 (xx)
EA (1) EA019893B1 (xx)
ES (6) ES2601820T5 (xx)
FI (1) FI2487161T4 (xx)
FR (4) FR17C1002I2 (xx)
HR (5) HRP20161476T4 (xx)
HU (6) HUE031707T2 (xx)
IL (1) IL200550A0 (xx)
LT (9) LT3150586T (xx)
LU (1) LUC00156I2 (xx)
MX (1) MX2009008935A (xx)
NO (4) NO2017002I2 (xx)
NZ (1) NZ579802A (xx)
PL (3) PL2487162T3 (xx)
PT (6) PT2487163T (xx)
SG (2) SG183059A1 (xx)
SI (1) SI3150586T1 (xx)
TW (1) TWI533868B (xx)
WO (1) WO2008103949A1 (xx)
ZA (1) ZA200905882B (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
NZ553405A (en) 2004-07-27 2010-03-26 Gilead Sciences Inc Nucleoside phosphonate conjugates as anti-HIV agents
ES2796275T3 (es) * 2006-07-07 2020-11-26 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
WO2008027932A2 (en) * 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
ES2601820T5 (es) * 2007-02-23 2024-10-31 Gilead Sciences Inc Moduladores de propiedades terapéutica de las farmacocinéticas
DK2487162T3 (en) 2007-02-23 2016-10-24 Gilead Sciences Inc Modulators of Pharmacokinetic properties terapeutikas
WO2009067225A2 (en) * 2007-11-20 2009-05-28 Concert Pharmaceuticals, Inc. Boceprevir derivatives for the treatment of hcv infections
CA2710679A1 (en) * 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
SG10201609006WA (en) * 2008-05-02 2016-12-29 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
KR101642527B1 (ko) 2008-07-08 2016-07-25 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 억제제 화합물의 염
TWI557117B (zh) 2008-12-09 2016-11-11 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
PT2393485E (pt) * 2009-02-06 2015-10-23 Gilead Sciences Inc Comprimidos bicamada que compreendem elvitegravir, cobicistat, emtricitabina e tenofovir
AU2015200637C1 (en) * 2009-02-06 2017-08-03 Gilead Sciences, Inc. Tablets for combination therapy
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
WO2010151672A2 (en) * 2009-06-26 2010-12-29 Georgetown University Amino acid derived ureas
EP2932970B1 (en) 2010-01-27 2018-03-21 VIIV Healthcare Company Antiviral therapy
WO2012045007A1 (en) 2010-10-01 2012-04-05 Gilead Sciences, Inc. Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
MX347512B (es) * 2010-11-19 2017-04-28 Gilead Sciences Inc Composiciones terapeuticas que comprenden hcl de rilpivirina y fumarato de disoproxilo de tenofovir.
US8987313B2 (en) 2010-12-21 2015-03-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
WO2012088178A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
US20130280212A1 (en) * 2010-12-21 2013-10-24 Gilead Sciences, Inc Inhibitors of cytochrome p450
EP2472320A2 (en) 2010-12-30 2012-07-04 Rohm and Haas Electronic Materials LLC Compositions comprising base-reactive component and processes for photolithography
WO2012151165A1 (en) * 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts
KR102058097B1 (ko) 2011-07-07 2019-12-20 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 다루나비어 복합 제제
AU2012296622C1 (en) 2011-08-16 2017-02-16 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
BR112014018738A8 (pt) 2012-02-03 2017-07-11 Gilead Sciences Inc Métodos e intermediários para preparo de agentes farmacêuticos
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
JP6059255B2 (ja) * 2012-02-03 2017-01-11 ギリアード サイエンシス インコーポレーテッド ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
CN104884063A (zh) * 2012-10-23 2015-09-02 西普拉有限公司 抗逆转录病毒药物组合物
HUE028284T2 (en) 2012-12-21 2016-12-28 Gilead Sciences Inc Polycyclic carbamoylpyridone compounds and their pharmaceutical use
EP2938603A1 (en) 2012-12-26 2015-11-04 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
SI3252058T1 (sl) 2013-07-12 2021-03-31 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje okužb s HIV
NO2865735T3 (xx) 2013-07-12 2018-07-21
PL3421033T3 (pl) 2013-10-07 2022-10-03 Bristol-Myers Squibb Holdings Ireland Unlimited Company Leczenie zakażenia wirusem hiv formulacją atazanawiru i kobicystatu
ES2689654T3 (es) 2013-12-03 2018-11-15 Mylan Laboratories Ltd. Preparación de productos intermedios de cobicistat
WO2015145324A1 (en) 2014-03-25 2015-10-01 Mylan Laboratories Ltd Process for the preparation of cobicistat
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (xx) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TW202412806A (zh) 2014-07-11 2024-04-01 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
CN106715421A (zh) * 2014-07-17 2017-05-24 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
SMT202100592T1 (it) 2014-12-26 2021-11-12 Univ Emory Derivati antivirali della n4-idrossicitidina
EP3277691B1 (en) 2015-04-02 2019-01-30 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN105198829B (zh) * 2015-08-15 2017-10-31 浙江永宁药业股份有限公司 一种可比司他中间体的制备方法及其中间体和用途
CN107513046B (zh) * 2016-06-15 2019-12-13 江苏欧信制药有限公司 一种可比司他的合成方法
JP6764017B2 (ja) * 2016-08-04 2020-09-30 ギリアード サイエンシーズ， インコーポレイテッド がんの処置での使用のためのコビシスタット
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
KR101908853B1 (ko) * 2017-05-17 2018-10-16 경북대학교 산학협력단 아세틸시코닌을 유효성분으로 함유하는 시토크롬 p450 동효소 억제용 조성물
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
EP3746425B1 (en) * 2018-01-30 2023-08-02 Panbela Therapeutics, Inc. Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1183026B1 (en) * 1999-06-04 2006-07-05 Abbott Laboratories Improved pharmaceutical formulations comprising ritonavir
US20060199851A1 (en) * 2005-03-02 2006-09-07 Kempf Dale J Novel compounds that are useful for improving pharmacokinetics

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199851A (en) * 1878-01-29 Improvement in circular saws
US115665A (en) * 1871-06-06 Improvement in folding-steps for carriages
US143314A (en) * 1873-09-30 Improvement in condenser-tube fastenings
US108617A (en) * 1870-10-25 Improvement in ore-pulverizers
US77295A (en) * 1868-04-28 theqdoee krausch
US181902A (en) * 1876-09-05 Improvement in bell toys
US127689A (en) * 1872-06-11 Improvement in differential pulley-blocks
US191319A (en) * 1877-05-29 Improvement in stoves
US99902A (en) * 1870-02-15 1870-02-15 Improvement in adjustable dials for travelers watches
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3882114A (en) 1967-10-26 1975-05-06 Oreal N-(morpholinomethyl carbamyl) cysteamine and glycine
GB1241024A (en) 1968-10-29 1971-07-28 Boehringer Sohn Ingelheim Pharmaceutical tablet base and a process for its manufacture
CA926708A (en) 1970-06-15 1973-05-22 Oushima Yoshitaka Process for producing spherical pellets
GB1339764A (en) 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
CH586568A5 (xx) 1972-04-10 1977-04-15 Hoffmann La Roche
US3957774A (en) 1972-04-17 1976-05-18 L'oreal N-morpholinomethyl-n-'-substituted ethyl and propylureas
DE2845326C2 (de) 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
HU186777B (en) 1981-07-09 1985-09-30 Magyar Tudomanyos Akademia Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them
US4603143A (en) 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2631620B1 (fr) 1988-05-19 1990-07-27 Rhone Poulenc Chimie Nouvelle silice precipitee absorbante et composition a base de cette s ilice
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5362912A (en) * 1989-05-23 1994-11-08 Abbott Laboratories Process for the preparation of a substituted diaminodiol
EP0428849A3 (en) 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
IE913840A1 (en) 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JPH06127981A (ja) 1992-03-03 1994-05-10 Fuainiteii Kk 複合複層ガラス及びそれを使用した窓
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DE10199053I1 (de) 1992-12-29 2002-08-29 Abbott Lab Inhibitoren der retroviralen Protease
WO1995005808A1 (en) 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5763464A (en) * 1995-11-22 1998-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US6348216B1 (en) 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4494539B2 (ja) 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
FR2767071B1 (fr) 1997-08-06 1999-09-10 Rhodia Chimie Sa Composition comprenant un liquide absorbe sur un support a base de silice precipitee
WO1999033792A2 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
OA12053A (en) 1999-10-06 2006-05-02 Tibotec Pharm Ltd HexahydrofuroÄ2,3-bÜfuran-3-yl-N-ä3-Ä(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)aminoÜ-1-benzyl-2-hydroxypropylücarbamate as retroviral protease inhibitor.
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2001082919A2 (en) * 2000-05-04 2001-11-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US20030035834A1 (en) 2000-05-26 2003-02-20 Pawan Seth Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
TWI290053B (en) 2000-09-19 2007-11-21 Daiichi Seiyaku Co Medicinal composition for preventing the generation of a disagreeable taste
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
DE10112651A1 (de) 2001-03-16 2002-09-19 Degussa Inhomogene Kieselsäuren als Trägermaterial
HRP20030858A2 (en) 2001-05-01 2005-08-31 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
DE10126163A1 (de) 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
CN100579514C (zh) 2001-07-06 2010-01-13 生命周期药物公司 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
WO2003047551A1 (en) 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
JP4523281B2 (ja) * 2002-01-17 2010-08-11 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
US6926906B2 (en) 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
US6726448B2 (en) 2002-05-15 2004-04-27 General Electric Company Ceramic turbine shroud
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
DK1564210T5 (da) * 2002-11-20 2010-05-03 Japan Tobacco Inc 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
US7189416B2 (en) 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
JP2004184681A (ja) 2002-12-03 2004-07-02 Konica Minolta Holdings Inc 熱現像感光材料
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CA2516448A1 (en) 2003-02-19 2004-09-02 H. Lundbeck A/S Method for preparation of an agglomerate using melt agglomeration
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
JP4018664B2 (ja) 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
DE10337198A1 (de) 2003-08-13 2005-03-17 Degussa Ag Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
JP2005075826A (ja) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
JP2005091988A (ja) 2003-09-19 2005-04-07 Konica Minolta Medical & Graphic Inc 熱現像感光材料及び画像形成方法
US20070122482A1 (en) 2003-10-03 2007-05-31 Per Holm Method for preparing modified release pharmaceutical compositions
US20050096390A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20050095287A1 (en) 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20070298108A1 (en) 2004-03-01 2007-12-27 Peter Svete Pharmaceutical Formulation
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
WO2005105040A2 (en) 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP3287130A1 (en) 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
JP2006003701A (ja) 2004-06-18 2006-01-05 Konica Minolta Medical & Graphic Inc 熱現像感光材料および画像形成方法
BRPI0512660A (pt) 2004-06-28 2008-04-01 Lifecycle Pharma As tablete carregável, e, método para a preparação de um tablete
MXPA06015108A (es) 2004-07-06 2007-03-26 Abbott Lab Profarmacos inhibidores de la proteasa del virus de la inmunodeficiencia humana.
AR045841A1 (es) 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
US20060084628A1 (en) 2004-10-19 2006-04-20 Achillion Pharmaceuticals Combination therapy for treating viral infections
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US20070014854A1 (en) 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
EP1978939A2 (en) 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
SG170796A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Us Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007076874A1 (en) 2006-01-05 2007-07-12 Lifecycle Pharma A/S Disintegrating loadable tablets
US20100285157A1 (en) 2006-02-20 2010-11-11 Asahi Breweries, Ltd Granules, tablets and method of producing the same
EP1998759A2 (en) 2006-03-23 2008-12-10 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
ES2796275T3 (es) 2006-07-07 2020-11-26 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
CL2007002331A1 (es) 2006-08-10 2008-04-18 Cipla Ltd Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih.
WO2008027932A2 (en) 2006-08-31 2008-03-06 Abbott Laboratories Cytochrome p450 oxidase inhibitors and uses thereof
US20090281132A1 (en) 2006-09-04 2009-11-12 Kiran Kumar Narsaiah Velaveni Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
ES2601820T5 (es) 2007-02-23 2024-10-31 Gilead Sciences Inc Moduladores de propiedades terapéutica de las farmacocinéticas
EA200971093A1 (ru) 2007-06-29 2010-08-30 Джилид Сайэнс, Инк. Терапевтические композиции и их применение
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
TWI448457B (zh) 2007-07-06 2014-08-11 Gilead Sciences Inc 治療劑的藥物動力學性質之調節劑
KR20170072365A (ko) 2007-12-27 2017-06-26 백스터 인터내셔널 인코포레이티드 생리학적으로 수용가능한 중합체 분자를 특이적으로 검출하기 위한 방법 및 조성물
SG10201609006WA (en) * 2008-05-02 2016-12-29 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
PT2393485E (pt) 2009-02-06 2015-10-23 Gilead Sciences Inc Comprimidos bicamada que compreendem elvitegravir, cobicistat, emtricitabina e tenofovir
EP2238979A1 (en) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
JP6059255B2 (ja) 2012-02-03 2017-01-11 ギリアード サイエンシス インコーポレーテッド ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1183026B1 (en) * 1999-06-04 2006-07-05 Abbott Laboratories Improved pharmaceutical formulations comprising ritonavir
US20060199851A1 (en) * 2005-03-02 2006-09-07 Kempf Dale J Novel compounds that are useful for improving pharmacokinetics

Also Published As

Publication number Publication date
AP3915A (en) 2016-11-29
CN101679325B (zh) 2013-08-28
JP2015078241A (ja) 2015-04-23
PT2487161T (pt) 2016-11-10
FR17C1000I2 (fr) 2019-03-22
US20080207620A1 (en) 2008-08-28
US20100189687A1 (en) 2010-07-29
FR17C1002I1 (fr) 2017-03-17
AP2009004964A0 (en) 2009-10-31
DK2487166T3 (en) 2017-02-20
US20170158647A1 (en) 2017-06-08
PL2487161T3 (pl) 2017-03-31
JP2010519314A (ja) 2010-06-03
PL3150586T3 (pl) 2020-06-01
NO2017003I1 (no) 2017-01-12
CY2017002I2 (el) 2017-06-28
NO2020011I1 (no) 2020-06-05
TW200904419A (en) 2009-02-01
FR20C1021I1 (fr) 2020-07-31
US8148374B2 (en) 2012-04-03
SI3150586T1 (sl) 2020-03-31
JP2021001236A (ja) 2021-01-07
CY1118292T1 (el) 2017-06-28
HRP20200349T1 (hr) 2020-06-12
EP4403221A2 (en) 2024-07-24
FR17C1002I2 (fr) 2019-03-22
LT2487162T (lt) 2016-11-10
EP3150586B1 (en) 2020-01-08
LUC00156I2 (xx) 2021-02-17
ES2602784T3 (es) 2017-02-22
LT2487161T (lt) 2016-11-10
US20120237478A1 (en) 2012-09-20
CY1118219T1 (el) 2017-06-28
FR17C1001I1 (fr) 2017-03-17
HRP20161476T1 (hr) 2016-12-16
FR17C1000I1 (fr) 2017-03-17
LTPA2016040I1 (lt) 2017-01-10
KR20090122261A (ko) 2009-11-26
CY1118227T1 (el) 2017-06-28
US20160069915A1 (en) 2016-03-10
WO2008103949A1 (en) 2008-08-28
TWI533868B (zh) 2016-05-21
CY1118232T1 (el) 2017-06-28
EP2118082A1 (en) 2009-11-18
NO2017001I1 (no) 2017-01-12
CY2017001PI2 (el) 2017-09-13
KR20150056665A (ko) 2015-05-26
JP6147388B2 (ja) 2017-06-14
HRP20161476T4 (hr) 2024-07-05
LTC2487163I2 (lt) 2022-06-27
US20140017199A1 (en) 2014-01-16
JP6192776B2 (ja) 2017-09-06
HK1137451A1 (en) 2010-07-30
CN103435570A (zh) 2013-12-11
LTC3150586I2 (lt) 2022-05-10
HUE031707T2 (en) 2017-07-28
US20150139948A1 (en) 2015-05-21
JP2017171695A (ja) 2017-09-28
LTC2487166I2 (lt) 2021-10-11
CY2020011I1 (el) 2020-11-25
JP2019059790A (ja) 2019-04-18
CA2678907C (en) 2014-06-17
CY2017003I1 (el) 2017-06-28
MX2009008935A (es) 2009-11-02
ES2601820T3 (es) 2017-02-16
JP2016121193A (ja) 2016-07-07
JP6147282B2 (ja) 2017-06-14
CN103435570B (zh) 2015-06-10
LT2487163T (lt) 2016-10-25
AU2008218186A1 (en) 2008-08-28
PT2487163T (pt) 2016-11-21
JP5554300B2 (ja) 2014-07-23
LTPA2016038I1 (lt) 2017-01-10
NZ579802A (en) 2012-04-27
AU2008218186B2 (en) 2014-01-23
EP2487161B1 (en) 2016-08-10
EP3150586A1 (en) 2017-04-05
PT2487166T (pt) 2016-10-17
HRP20161371T1 (hr) 2016-12-02
EA019893B1 (ru) 2014-07-30
CA2678907A1 (en) 2008-08-28
LTPA2020508I1 (lt) 2020-06-25
NO2017002I1 (no) 2017-01-12
LUC00156I1 (xx) 2020-06-02
HUS2000013I1 (hu) 2020-06-29
EP2487161A1 (en) 2012-08-15
AU2008218186C1 (en) 2014-07-17
AP2013007042A0 (en) 2013-08-31
ES2603645T3 (es) 2017-02-28
JP2016172773A (ja) 2016-09-29
US8486942B2 (en) 2013-07-16
CY2017002I1 (el) 2017-06-28
KR101664154B1 (ko) 2016-10-10
ES2779826T3 (es) 2020-08-20
CY2020011I2 (el) 2020-11-25
LT3150586T (lt) 2020-03-10
HUS1600054I1 (hu) 2017-01-30
ES2525454T3 (es) 2014-12-23
HUE029866T2 (en) 2017-03-28
KR101577698B1 (ko) 2015-12-15
SG183059A1 (en) 2012-08-30
ZA200905882B (en) 2018-12-19
EA200901155A1 (ru) 2010-02-26
CY2017003I2 (el) 2017-06-28
LTC2487162I2 (lt) 2022-06-27
SG10201705929QA (en) 2017-08-30
HRP20161428T1 (hr) 2016-12-16
EP4403221A3 (en) 2024-10-09
EP3689353A1 (en) 2020-08-05
PL2487161T5 (pl) 2024-09-09
LT2487166T (lt) 2016-11-10
EP2487161B2 (en) 2024-06-05
FI2487161T4 (fi) 2024-06-06
CY2017001PI1 (el) 2017-09-13
JP2014088441A (ja) 2014-05-15
CY1122761T1 (el) 2020-11-25
ES2603617T3 (es) 2017-02-28
PL2487162T3 (pl) 2017-03-31
DK3150586T3 (da) 2020-02-17
EP2118082B1 (en) 2014-10-01
AR065439A1 (es) 2009-06-10
LTPA2016039I1 (lt) 2017-01-10
PT2487162T (pt) 2016-11-23
HRP20161502T1 (hr) 2016-12-16
IL200550A0 (en) 2010-05-17
CN101679325A (zh) 2010-03-24
JP2011231132A (ja) 2011-11-17
PT2118082E (pt) 2014-12-12
BRPI0807581A2 (pt) 2014-07-01
PT3150586T (pt) 2020-03-31
HUE029843T2 (en) 2017-04-28
HUE029842T2 (en) 2017-04-28
NO2017002I2 (no) 2017-01-12
ES2601820T5 (es) 2024-10-31
FR17C1001I2 (fr) 2019-05-17
US9891239B2 (en) 2018-02-13
JP4881446B2 (ja) 2012-02-22

Similar Documents

Publication Publication Date Title
HUS2000013I1 (hu) Gyógyszerek farmakokinetikai tulajdonságainak modulátorai
AP2985A (en) Modulators of pharmacokinetic properties of therapeutics
IL202624A0 (en) Modulators of pharmacokinetic properties of therapeutics
HUS1600053I1 (hu) Terápiás szerek farmakokinetikai paramétereinek modulálása